Qingshu R. Lu
Singapore, Singapore
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.
Journal: The Lancet. Infectious diseases
Published: October 24, 2024
Shared patterns of glial transcriptional dysregulation link Huntington's disease and schizophrenia.
Journal: Brain : a journal of neurology
Published: September 23, 2023
Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.
Journal: The Journal of infectious diseases
Published: July 12, 2023
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Journal: The New England journal of medicine
Published: February 22, 2023
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Journal: The Lancet. Infectious diseases
Published: November 02, 2022
Pre- and apnoeic high-flow oxygenation for rapid sequence intubation in the emergency department (the Pre-AeRATE trial): A multicentre randomised controlled trial.
Journal: Annals of the Academy of Medicine, Singapore
Published: April 04, 2022
Effects of Increasing Concentrations of Rifampicin on Different Mycobacterium tuberculosis Lineages in a Whole-Blood Bactericidal Activity Assay.
Journal: Antimicrobial agents and chemotherapy
Published: December 06, 2021
Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial.
Journal: Journal of the American Medical Directors Association
Published: August 13, 2021
NEURoaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo-controlled randomized trial.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: June 02, 2020
Frequency and Clinical Impact of Serious Adverse Events on Post-Stroke Recovery with NeuroAiD (MLC601) versus Placebo: The CHInese Medicine Neuroaid Efficacy on Stroke Recovery Study.
Journal: Cerebrovascular diseases (Basel, Switzerland)
Published: October 15, 2019
Impact of selective immune-cell depletion on growth of Mycobacterium tuberculosis (Mtb) in a whole-blood bactericidal activity (WBA) assay.
Journal: PloS one
Published: February 03, 2019
Last Updated: 09/26/2026